Dr. Sheffield is an adult rheumatologist who received the following referral request from a family doctor: “Please see this 22-year-old male with a history of juvenile arthritis for ongoing care. I have only seen him once, and have no previous medical records.” Dr. Sheffield meets with Paul, who reports that he has had arthritis since…
Rheumatologists and rheumatology health professionals make a difference every day in the lives of patients. And through the work of many devoted members, the College takes that commitment beyond the care setting and into the policy arena to Advance Rheumatology! on Capitol Hill and in state capitols across the country. I want to take a…
The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…
The pathogenesis of and new classification criteria for MAS
Review of clinical research on methotrexate therapy, effect on patients’ functionality, tolerability, adverse events
Lack of efficacy, poor DAS scores may be misinterpreted as a drug failure
Overview of OA pathogenesis, recent discoveries suggest new treatment strategies are possible
With the U.S. FDA’s first approval of a biosimilar drug earlier this month, rheumatologists stress the need to ensure safety, efficacy of such drugs in treating rheumatic diseases
Rheumatologist Richard Brasington, MD, says patient John Reigstad’s active participation in treatment decisions shows how much improving quality of life matters
The ACR shares highlights of in-development guidelines for RA combination strategies, live vaccines and biologics